Oncotype DX Genomic Prostate Score

Communicating Results to Your Patient

Prostate cancer patient and urologist 

It can be overwhelming for patients to remember all the information they are told during an office visit. You may download resources that may be helpful in discussing prostate cancer and genomic testing with your patients.

Prostate cancer

  • Prostate cancers vary with respect to their aggressiveness and the need for immediate treatment.1
  • Low risk prostate cancer is common in the United States2 but 10 year mortality in low risk patients is about 1%, regardless of initial management strategy.3
  • Many prostate cancers are slow growing and unlikely to spread in the short term; this sort of prostate cancer may be well managed with active surveillance.4,5

Treatment options

  • Some men with low-risk prostate cancer will live out their life without ever being bothered by the disease or needing definitive treatment like surgery or radiation.
  • Active surveillance is a management plan for carefully monitoring prostate cancer without removing or radiating it—meaning the patient can avoid or delay the side effects of immediate treatment, including urinary, bowel, and sexual problems.
  • Under active surveillance, patients have regular check-ups and ongoing testing, typically including blood tests for prostate-specific antigen (PSA) levels, regular digital rectal exams, and repeat biopsies as needed.
  • Even with close monitoring via active surveillance, cancer may show signs of progression and treatment may be required; for the vast majority of men outcomes from delayed treatment remain excellent.4,5

Oncotype DX Genomic Prostate Score (GPS)

  • A genomic test measures the expression of genes within a sample of tumor tissue. The Oncotype DX GPS test is a genomic test, and the results can help determine how aggressive the patient’s cancer is.
  • For patients who have been recently diagnosed with low- or intermediate-risk prostate cancer and have not yet begun treatment with surgery or radiation therapy, the Oncotype DX GPS might be appropriate to help guide management decisions. The GPS isn’t intended for men with advanced prostate cancer.

Preparing for test results

 

Oncotype DX Genomic Prostate Score - Understanding the Results

What your patients can prepare for prior to an appointment with you to discuss their Oncotype DX Genomic Prostate Score results.



PDFs

Patient Brochure
A guide to the Oncotype DX GPS for men newly diagnosed with early-state prostate cancer.

Online Portal Guide
A guide to navigating prostate cancer information online.

Treatment Chart
A look at the pros and cons of possible treatment options for prostate cancer.

Active Surveillance Infographic
A visual representation of the importance of active surveillance as a treatment option.

REFERENCES

1. NCCN 2017 Prostate Cancer Guidelines version 1
2. SEER, https://seer.cancer.gov/statfacts/html/prost.html, accessed 3/13/17.
3. Hamdy et al. N Engl J Med 2016.
4. Tosoian et al. Nat Rev Urol 2016.
5. Yamamoto et al. J Urol 2016.

 

Get Our Patient Brochure

Download

Video Snippet:
Choosing Active Surveillance

 

In this short video, David Albala, MD, explains how Oncotype DX GPS test has doubled the number of his patients who choose active surveillance.

Interactive
Report Viewer

Take an interactive tour of the Oncotype DX Genomic Prostate Score report.

Start Report Guide
Physician Login

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™